Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials

• Main Authors: Yunda Huang (Author), Shelly Karuna (Author), Lindsay N. Carpp (Author), Daniel Reeves (Author), Amarendra Pegu (Author), Kelly Seaton (Author), Kenneth Mayer (Author), Joshua Schiffer (Author), John Mascola (Author), Peter B. Gilbert (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infection. In a modeling exercise, we used two models to predict the overall prevention efficacy (PE) of each VRC01 dose in preventing HIV infection. For t...